OncoResponse focuses on developing cancer immunotherapies within the immuno-oncology sector. The company specializes in utilizing immune responses to create therapeutics intended to support the body's immune system in fighting cancer, particularly through the development of monoclonal antibodies that target the tumor microenvironment. Its pipeline includes a range of preclinical candidates designed to address immunosuppression and improve immune activity against tumors. It was founded in 2015 and is based in Seattle, Washington.

ImmunoMet Therapeutics develops anti-fibrotic and anti-tumor therapies by targeting cellular metabolism. The company specializes in a lead molecule, IM156, which is a protein complex 1 (PC1) inhibitor designed to affect the oxidative phosphorylation (OXPHOS) pathway in mitochondria, aiming to decrease cell growth in fibrosis and certain cancer cells. It primarily sells to the healthcare and pharmaceutical sectors, with ongoing clinical trials and therapeutic offerings. It was founded in 2015 and is based in Houston, Texas.

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies targeting myeloid cells within the immunology and oncology sectors. The company offers a portfolio of biotherapeutics, including antagonist antibodies designed to modulate or deplete specific subsets of myeloid cells, to treat blood cancers, solid tumors, and autoimmune diseases. Immune-Onc's pipeline includes several candidates in various stages of clinical development, targeting receptors such as LILRB2 and LILRB4. It was founded in 2016 and is based in Palo Alto, California.

Fortis Therapeutics is a biotechnology company focused on developing therapeutics for cancer treatment. Their offerings include therapies that target CD46 proteins in tumor cells while sparing normal tissues. The company's approach emphasizes precision medicine. It was founded in 2016 and is based in La Jolla, California.

Epsilogen is a biotechnology company that specializes in the development of immunoglobulin E (IgE) antibodies for cancer treatment. The company focuses on creating therapeutic antibodies that target solid tumors, utilizing IgE's properties such as potency, tumor access, and tissue half-life. Epsilogen's lead product, MOv18 IgE, is designed to target ovarian cancer and has progressed to clinical trials. Epsilogen was formerly known as IGEM Therapeutics. It was founded in 2016 and is based in London, United Kingdom.

OncoOne is a biotech company focused on developing precision medicines for the treatment of inflammation and cancer within the healthcare sector. The company develops precision medicines that target tumor-associated molecules and deliver antibody-based therapies to affected organs. OncoOne's main services include the development of therapeutics through its Anti-oxMIF and PreTarg-it platforms, which are aimed at addressing needs in oncology and chronic inflammation. It was founded in 2018 and is based in Klosterneuburg, Austria.